ORP vs. RALP re-visited

A newly published report in The Lancet Oncology has pretty much finally confirmed what many of us have been assuming for a long time now: … READ MORE …

Promising new data on lutetium-177 PSMA radioligand therapy

According to a presentation given last week in San Francisco, lutetium-177 (177Lu) prostate-specific membrane antigen (PSMA) radioligand therapy has significant clinical activity in men with metastatic prostate cancer (as opposed to just in men with very late stages of prostate cancer). … READ MORE …

VTP in the focal therapy of low-risk, localized prostate cancer

We have previously reported data from the 2-year follow-up of the patients participating in the PCM301 trial of vascular targeted phototherapy (VTP) — a form of prostate hemiablation — compared to active surveillance in the treatment of low-risk, localized prostate cancer. New data at 4 years of follow-up have now been published in the Journal of Urology. … READ MORE …

MRI-guided biopsy in the diagnosis of prostate cancer (again)

The results of the so-called PRECISION trial were just published in the New England Journal of Medicine this morning. … READ MORE …

First randomized clinical trial of SBRT reports primary outcome

In the first trial ever to randomly assign patients to extreme hypofractionation, primary radiation therapy delivered in just seven treatments had the same effectiveness and safety as 39 treatments. … READ MORE …

Long-term data on active surveillance from MSKCC

A presentation at the upcoming annual meeting of the American Urological Association (AUA) will provide data on outcomes of men initially managed on active surveillance at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York over the past 17 years. … READ MORE…

The MEAL study — another update: data coming soon

In October last year we had expressed the hope that data from the Men’s Eating and Living (MEAL) study would be presented at a major medical meeting this year. … READ MORE …